Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2025.073045
Journal Menu
Special Issues
Table of Content

All issues

Online First

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Open Access

REVIEW

Ferroptosis as a Translational Axis in Small Cell Lung Cancer: A Systematic Review of Redox Pathways and Precision Oncology Prospects

Donatella Coradduzza1,#, Anna La Salvia2,#, Giuseppe Fanciulli3, Maria Rosaria De Miglio3,*
1 Department of Biomedical Sciences, University of Sassari, Sassari, 07100, Italy
2 National Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, 00161, Italy
3 Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, 07100, Italy
* Corresponding Author: Maria Rosaria De Miglio. Email: email
# These authors contributed equally to this work
(This article belongs to the Special Issue: Tumor Biomarkers for Diagnosis, Prognosis and Targeted Therapy)

Oncology Research https://doi.org/10.32604/or.2025.073045

Received 09 September 2025; Accepted 12 December 2025; Published online 04 January 2026

Abstract

Background: An increasing number of studies have shown that ferroptosis is related to the initiation and development of small cell lung cancer (SCLC). The systematic review aimed to summarize the characteristics of ferroptosis from its pathogenetic role to translational therapeutic implications in SCLC. Methods: This systematic review, registered in PROSPERO (CRD420251090058), followed PRISMA 2020 guidelines. Comprehensive research of PubMed, Scopus, and Web of Science was performed for studies published between January 2010 and July 2025 investigating ferroptosis mechanisms, genetic or pharmacological modulation, or molecular profiling in SCLC. Two reviewers independently performed data extraction and quality assessment. Results: Nineteen preclinical studies met the inclusion criteria. Key regulators included solute carrier family 7 member 11 (SLC7A11), glutathione peroxidase 4 (GPX4), ferroptosis suppressor protein 1 (FSP1), and acyl-CoA synthetase long chain family member 4 (ACSL4). The molecular subtypes of SCLC, achaete-scute homolog 1 (ASCL1), neuronal differentiation 1 (NEUROD1), POU class 2 homeobox 3 (POU2F3), and Yes1 associated transcriptional regulator (YAP1) exhibit differential ferroptosis gene expressions, influencing therapeutic responsiveness. Non-neuroendocrine subtypes are more ferroptosis-prone, whereas neuroendocrine variants display enhanced antioxidant defenses. Ferroptosis induction also promotes immune activation through stimulator of interferon genes (STING)-mediated CD8+ T-cell recruitment. Conclusions: Ferroptosis constitutes a promising therapeutic axis in SCLC. Integrating ferroptosis biomarkers into molecular stratification frameworks could refine patient selection and support precision oncology strategies, warranting further translational and clinical validation.

Keywords

Small cell lung cancer; ferroptosis; lipid peroxidation; glutathione peroxidase 4; solute carrier family 7 member 11; molecular subtypes; immunotherapy; oxidative stress; regulated cell death; translational oncology; systematic review

  • 99

    View

  • 22

    Download

  • 0

    Like

Related articles
Copyright© 2026 Tech Science Press
© 1997-2026 TSP (Henderson, USA) unless otherwise stated

Share Link